Surrozen, Inc./DE Amortization of Debt Discount (Premium)
Surrozen, Inc./DE (SRZN) reported Amortization of Debt Discount (Premium) of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2025-03-31
- Surrozen, Inc./DE amortization of debt discount (premium) for the quarter ending 2024-12-31 was $0.00.
- Surrozen, Inc./DE amortization of debt discount (premium) for the quarter ending 2024-09-30 was $0.00.
- Surrozen, Inc./DE amortization of debt discount (premium) for the quarter ending 2024-06-30 was $0.00.
- Surrozen, Inc./DE amortization of debt discount (premium) for the quarter ending 2024-03-31 was $0.00.
- Surrozen, Inc./DE amortization of debt discount (premium) for fiscal 2024 was $0.00.
- Surrozen, Inc./DE amortization of debt discount (premium) for fiscal 2023 was -$732.00K, a 777.78% decline from fiscal 2022.
- Surrozen, Inc./DE amortization of debt discount (premium) for fiscal 2022 was $108.00K.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $0.00 derived: sum of 2 quarters · filed 2025-03-31 | $0.00 derived: sum of 3 quarters · filed 2025-03-31 | $0.00 10-K · filed 2025-03-31 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | -$44.00K derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $0.00 10-Q · filed 2024-08-12 | -$44.00K derived: sum of 3 quarters · filed 2025-03-31 | -$252.00K derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-08 | -$44.00K derived: sum of 2 quarters · filed 2025-03-31 | -$252.00K derived: sum of 3 quarters · filed 2025-03-31 | -$491.00K derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-12-31 | -$44.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$252.00K derived: sum of 2 quarters · filed 2025-03-31 | -$491.00K derived: sum of 3 quarters · filed 2025-03-31 | -$732.00K 10-K · filed 2025-03-31 |
| 2023-09-30 | -$208.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$447.00K derived: sum of 2 quarters · filed 2024-11-06 | -$688.00K 10-Q · filed 2024-11-06 | -$850.00K derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$239.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$480.00K 10-Q · filed 2024-08-12 | -$642.00K derived: sum of 3 quarters · filed 2024-08-12 | -$607.00K derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$241.00K 10-Q · filed 2024-05-08 | -$403.00K derived: sum of 2 quarters · filed 2024-05-08 | -$368.00K derived: sum of 3 quarters · filed 2024-05-08 | -$249.00K derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | -$162.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-10 | -$127.00K derived: sum of 2 quarters · filed 2024-04-10 | -$8.00K derived: sum of 3 quarters · filed 2024-04-10 | $108.00K 10-K · filed 2024-04-10 |
| 2022-09-30 | $35.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $154.00K derived: sum of 2 quarters · filed 2023-11-08 | $270.00K 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $119.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $235.00K 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | $116.00K 10-Q · filed 2023-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |